Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864 | 0.98 | KEAP1 (0.67) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL28338568 | 0.95 | KEAP1 (0.64) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL8591123 | 0.88 | KEAP1 (0.55) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL9135914 | 0.85 | FFAR1 (0.50) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL1912568 | 0.85 | FFAR1 (0.71) | KEAP1FFAR1HDAC2HDAC1HTT | |
| Tetrahydrofuran SCHEMBL28927730 | 0.85 | FKBP1A (0.57) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL61491 | 0.84 | HDAC1 (0.69) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| Trifluoroacetamide SCHEMBL28335370 | 0.83 | CES1 (0.50) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 | |
| SCHEMBL384438 | 0.83 | MAPT (0.68) | KEAP1HDAC2HDAC8HDAC6TDP1 | |
| SCHEMBL27538484 | 0.83 | HDAC1 (0.67) | KEAP1ALDH1A1FFAR1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | KEAP1 590/4885ALDH1A1 2528/4885FFAR1 1063/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | KEAP1 436/4885ALDH1A1 2250/4885FFAR1 1119/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | KEAP1 590/4885ALDH1A1 2528/4885FFAR1 1063/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | KEAP1 618/4885ALDH1A1 2075/4885FFAR1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.